CO2023000194A2 - Administración de sulcardina para el tratamiento de fibrilación auricular aguda - Google Patents

Administración de sulcardina para el tratamiento de fibrilación auricular aguda

Info

Publication number
CO2023000194A2
CO2023000194A2 CONC2023/0000194A CO2023000194A CO2023000194A2 CO 2023000194 A2 CO2023000194 A2 CO 2023000194A2 CO 2023000194 A CO2023000194 A CO 2023000194A CO 2023000194 A2 CO2023000194 A2 CO 2023000194A2
Authority
CO
Colombia
Prior art keywords
sulcardine
administration
treatment
atrial fibrillation
acute atrial
Prior art date
Application number
CONC2023/0000194A
Other languages
English (en)
Spanish (es)
Inventor
Gary Elliott
Mireille Gillings
Robert Goodenow
Jay Mason
Waldemar Radziszewski
Suzanne Romano
Original Assignee
Huyabio Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huyabio Int Llc filed Critical Huyabio Int Llc
Publication of CO2023000194A2 publication Critical patent/CO2023000194A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2023/0000194A 2020-06-12 2023-01-10 Administración de sulcardina para el tratamiento de fibrilación auricular aguda CO2023000194A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
CO2023000194A2 true CO2023000194A2 (es) 2023-03-27

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000194A CO2023000194A2 (es) 2020-06-12 2023-01-10 Administración de sulcardina para el tratamiento de fibrilación auricular aguda

Country Status (14)

Country Link
US (2) US11813245B2 (https=)
EP (1) EP4164633A4 (https=)
JP (1) JP2023529196A (https=)
KR (1) KR20230024347A (https=)
CN (1) CN116723836A (https=)
AU (1) AU2021288056A1 (https=)
BR (1) BR112022025216A2 (https=)
CA (1) CA3182015A1 (https=)
CL (1) CL2022003501A1 (https=)
CO (1) CO2023000194A2 (https=)
IL (1) IL298907A (https=)
MX (1) MX2022015834A (https=)
PH (1) PH12022553396A1 (https=)
WO (1) WO2021252959A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
EP2501381B1 (en) * 2009-11-17 2017-07-26 Huya Bioscience International LLC Treatment of atrial fibrillation
EP2501380B1 (en) * 2009-11-17 2016-01-27 Huya Bioscience International LLC Slow infusion of sulcardine and its salts
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
CN113453677A (zh) * 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) * 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Also Published As

Publication number Publication date
PH12022553396A1 (en) 2024-04-22
JP2023529196A (ja) 2023-07-07
MX2022015834A (es) 2023-04-04
CL2022003501A1 (es) 2023-06-09
KR20230024347A (ko) 2023-02-20
WO2021252959A1 (en) 2021-12-16
US20240058304A1 (en) 2024-02-22
IL298907A (en) 2023-02-01
CA3182015A1 (en) 2021-12-16
EP4164633A4 (en) 2024-07-31
EP4164633A1 (en) 2023-04-19
US12465587B2 (en) 2025-11-11
US11813245B2 (en) 2023-11-14
BR112022025216A2 (pt) 2023-04-04
US20210386708A1 (en) 2021-12-16
AU2021288056A1 (en) 2023-02-09
CN116723836A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
NI202100009A (es) Métodos para reducir la necesidad de revascu
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
MX2022005467A (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto con fibrilación auricular y/o aleteo auricular.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
ZA202104166B (en) Sulcardine administration for treatment of acute atrial fibrillation
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
CO2023000194A2 (es) Administración de sulcardina para el tratamiento de fibrilación auricular aguda
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2026000232A (es) Compuestos de 1,2,4-trioxano y composiciones que comprenden los mismos para uso en la prevencion y el tratamiento del cancer
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
CO2023007955A2 (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d